New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
09:18 EDTPCYCPharmacyclics price target raised to $166 from $154 at Roth Capital
Roth Capital increased its price target on Pharmacyclics after the FDA approved the company's IMBRUVICA for chronic lymphocytic leukemia. The firm expects sales of the drug to be strong and keeps a Buy rating on the shares.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for PCYC

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use